BiotechTube

17 beta estradiol

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Turner Syndrome

Conditions

Turner Syndrome, Hypogonadism, Premature Ovarian Failure

Trial Timeline

Jan 1, 2001 → Jun 1, 2004

NCT ID
NCT00140998

About 17 beta estradiol

17 beta estradiol is a phase 3 stage product being developed by Eli Lilly for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00140998. Target conditions include Turner Syndrome, Hypogonadism, Premature Ovarian Failure.

What happened to similar drugs?

3 of 7 similar drugs in Turner Syndrome were approved

Approved (3) Terminated (0) Active (4)
🔄SomatropinEli LillyPhase 3
✅HumatropeEli LillyApproved
🔄Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
✅r-hGHMerckApproved
🔄Somapacitan + Norditropin®Novo NordiskPhase 3
✅estradiolNovo NordiskApproved
🔄Somatropin (rDNA origin)IpsenPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00140998Phase 3Completed

Competing Products

10 competing products in Turner Syndrome

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
40
HumatropeEli LillyApproved
43
Somatropin + Ethinyl estradiol + Medroxyprogesterone acetateEli LillyPhase 3
40
r-hGHMerckApproved
43
Somapacitan + Norditropin®Novo NordiskPhase 3
44
estradiolNovo NordiskApproved
43
Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patchNovo NordiskPhase 1
21
somatotropinPfizerPre-clinical
26
Lonapegsomatropin + SomatropinAscendis PharmaPhase 2
36
Somatropin (rDNA origin)IpsenPhase 3
37